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Abstract
Endogenous serine protease inhibitors (serpins) are anti-inflammatory mediators with multiple biologic functions. Several
serpins have been reported to modulate HIV pathogenesis, or exhibit potent anti-HIV activity in vitro, but the efficacy of
serpins as therapeutic agents for HIV in vivo has not yet been demonstrated. In the present study, we show that heparin-
activated antithrombin III (hep-ATIII), a member of the serpin family, significantly inhibits lentiviral replication in a non-
human primate model. We further demonstrate greater than one log10 reduction in plasma viremia in the nonhuman
primate system by loading of hep-ATIII into anti-HLA-DR immunoliposomes, which target tissue reservoirs of viral
replication. We also demonstrate the utility of hep-ATIIII as a potential salvage agent for HIV strains resistant to standard
anti-retroviral treatment. Finally, we applied gene-expression arrays to analyze hep-ATIII-induced host cell interactomes and
found that downstream of hep-ATIII, two independent gene networks were modulated by host factors prostaglandin
synthetase-2, ERK1/2 and NFkB. Ultimately, understanding how serpins, such as hep-ATIII, regulate host responses during
HIV infection may reveal new avenues for therapeutic intervention.
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Introduction
Current HIV therapies employ combinations of small molecule
inhibitors that target viral proteins at different steps in the HIV
replication cycle in order to prevent the emergence of HIV
resistance to therapy [1,2,3,4]. Despite this strategy, resistance to
one or more drug classes can emerge, resulting in a population of
patients requiring salvage therapy [5]. The development of new
anti-HIV therapeutics that target host proteins important for the
virus life cycle could circumvent the problem of viral resistance.
Host cell proteins that influence viral replication are less mutable
than viral proteins, possibly offering an increased genetic barrier to
the development of drug resistance. An analogous therapeutic
concept has already proven efficacious in the treatment of HCV:
stimulation of the host innate immune response using interferon-
based therapy effectively blocks viral replication without induction
of viral resistance [6].
Endogenous serine protease inhibitors (serpins) are part of the
early innate immune response to viral infection that includes
mannose binding lectins, soluble CD14, defensins and antimicro-
bial peptides [7]. The main biologic function of serpins is the
blockage of protease activity involved in blood clotting and
complement activation. Serpins belong to a superfamily of proteins
that also regulate other inflammatory processes [8].
Serine protease inhibitors have a broad spectrum of anti-viral
activity against HIV, HCV, HSV and the influenza virus [9,10]. A
number of clinical observations suggest a role for the serpins in
controlling HIV infection and disease progression in the mucosa
and the peripheral blood. For example, (1) there is a barrier to
HIV transmission via the oral mucosa; this may be due to the anti-
viral activity of Secretory Leukocyte Inhibitor (SLPI) in saliva [11].
(2) a1-anti-trypsin, the most abundant serpin in blood, prevents
HIV replication in vitro at physiological concentrations; in addi-
tion, HIV replicates at a much higher rate in the blood of a1-anti-
trypsin-deficient individuals, suggesting a1-anti-trypsin might re-
duce viral replication in vivo [12]. (3) The anti-HIV activity of a1-
anti-trypsin is believed to be responsible for the relatively low
transmission rates of HIV through contaminated needles, com-
pared to that of HCV and HBV. (4) Furthermore, presence of the
a1-anti-trypsin allelic variants M2 and A332A is associated with
enhanced HIV-1 acquisition [13].
Antithrombin III (ATIII), a serpin with a role in the coagulation
cascade, exhibits potent anti-HIV activity. ATIII exists in three
different forms under physiological conditions. In its inactive latent
(L) form, ATIII circulates with its reactive COOH-terminal loop
not fully exposed, thereby preventing its binding to thrombin.
Upon binding to heparin, ATIII undergoes a conformational
change to an activated, or stressed (S) form (here also termed hep-
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thus increasing the binding of thrombin by 100-fold. The resultant
ATIII-thrombin complex eventually dissociates with the release of
thrombin and an ATIII with a cleaved reactive loop, inducing
a conformational change of ATIII to a relaxed (R) form.
A proteolytically cleaved form of ATIII was originally
discovered to be a CD8
+ T cell anti-HIV factor (CAF) - a non-
cytolytic innate immune response in HIV-1 long-term non-
progressors [14,15]. The S form of ATIII has greater antiviral
activity against HIV and the simian immunodeficiency virus (SIV)
than the R form; the L form has no anti-viral activity [14]. Hep-
ATIII is up to 10-fold more potent at inhibiting HIV than the non-
activated form of ATIII [16]. When compared to other serpins
with anti-HIV activity, a1-antitrypsin and SLPI, heparin-activated
antithrombin III (hep-ATIII) displays up to 10
6 fold higher anti-
HIV activity in vitro [11,12,14,16,17,18]. The anti-viral activity of
hep-ATIII and ATIII is mediated at least in part by host cell
factors prostaglandin synthetase 2 (PTGS2) and transcription
factor NFkB [9]. Two hundred-fold less hep-ATIII was required
as compared to non-activated ATIII to elicit equivalent changes in
gene transcription of these host cell factors [9].
In the present study, we sought to validate hep-ATIII as an HIV
therapeutic using in vitro, humanized mouse and preclinical
primate models of HIV infection. In order to evaluate the
potential utility of ATIII as a salvage agent in patients with
multidrug resistant HIV, we assessed the ability of hep-ATIII to
inhibit a range of drug-resistant HIV-1 isolates in vitro, and in
humanized mice infected with highly drug resistant HIV-1. In
addition, we studied the effects of ATIII treatment in rhesus
macaques chronically infected with SIV. In a novel therapeutic
approach, we used anti-HLA-DR antibodies engrafted into
immunoliposomes to encapsulate hep-ATIII (termed ET-ATIII):
it has been shown that these immunoliposomes specifically target
HLA-DR positive cells in lymph nodes including monocytes,
macrophages and activated CD4
+ T lymphocytes, allowing
concentration of therapeutic ATIII in the main cellular reservoirs
of HIV and SIV [19]. Finally, we sought to understand the
mechanism by which hep-ATIII exerts its antiviral activity. We
studied the gene expression profiles of peripheral blood mono-
nuclear cells (PBMC) from SIV-infected macaques treated with
hep-ATIII, and identified the transcriptional networks activated or
repressed by hep-ATIII treatment. By elaborating the biologic
networks associated with HIV inhibition by the innate immune
system, we hoped to identify potential biomarkers of drug efficacy,
as well as potential future drug targets.
Materials and Methods
Ethics Statement
All animal experimental protocols were approved by the
Harvard Institutional Animal Care and Use Committee (IACUC)
[20]. Human blood sampling was reviewed and approved by the
Human Research Ethics Committee of the Beth Israel Deaconess
Medical Center (BIDMC) and Harvard Medical School (IRB
2006-P-000004). Written consent for human blood collection was
waived since no personal data were collected. Harvard Medical
School follows NIH guidelines for animal handling and has
Animal Welfare Assurance A3153-01 on file with the Office for
Protection of Research Risks. The institutions involved in the
studies maintain full accreditation from Association for Assessment
and Accreditation of Laboratory Animal Care.
Adult rhesus macaques (Macaca mulatta) were housed at the New
England Primate Research Center and Harvard Medical School,
a primate animal facility that is accredited by the Association for
the Assessment and Accreditation of Laboratory Animal Care
International. Research was conducted in compliance with the
Animal Welfare Act and other US federal statutes and regulations
relating to animals and experiments involving animals, and
adhered to principles stated in the Guide for the Care and Use
of Laboratory Animals, National Research Council, 1996. All
steps were taken to ameliorate the welfare and to avoid the
suffering of the animals in accordance with the ‘‘Weatherall report
for the use of non-human primates’’ recommendations. Animals
were housed either socially or in adjoining individual primate
cages allowing social interactions, under controlled conditions of
humidity, temperature and light (12-hour light/12-hour dark
cycles). Food and water were available ad libitum. Animals were fed
commercial monkey chow and treats by trained personnel.
Environmental enrichment consisted of commercial toys. Blood
draws were conducted under sedation by trained personnel under
the supervision of veterinarians.
Mice
NOD/scid/scid-beta-2 microglobulin (b2m) knockout mice
(Nod/Scid/b2m
null mice) (6–8 weeks) and C57BL/6 mice were
from the Jackson Laboratory (Bar Harbor, ME).
Source and Activation of ATIII
Recombinant human ATIII was produced in transgenic goats
by GTC Biotherapeutics (Framingham, MA). These transgenic
animals express human ATIII in their mammary glands and
secrete it into their milk. ATIII was purified from goat milk
through clarification through a 500-kDa tangential flow mem-
brane filtration unit, captured and then eluted through a heparin
affinity chromatography column. It was further purified by anion-
exchange chromatography and hydrophobic interaction chroma-
tography as described earlier [21]. The product had a biological
activity of 6 U/mg. It was more than 99% pure, as determined by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and by silver-staining, or by C4 high-pressure liquid
chromatography (HPLC).
Anti-viral ATIII activity was activated by incubation with
heparin as previously described and subsequently referred to as
hep-ATIII. Briefly, ATIII was incubated with equal amounts (w/
w) of heparin sodium (Polysciences, Warrington, PA, cat. no.
01491, 40–3 kDa fraction) overnight at 37uC to form a non-
covalent ATIII-heparin complex. Unbound heparin was then
removed by Sephacel 100 A ¨KTA FPLC (GE Health Care Life
Sciences, Piscataway, NJ) at 1 ml/min. Protein preparations
resulted in less than 5% (w/w) free heparin measured by FPLC
with refractive index detection and a formula described earlier
[16]. Protein purity was determined by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and silver staining
using a Bio-Rad kit (Bio-Rad Life Science, Hercules, CA) with
a 15% slab gel. Molecular weight was compared to a low-range
protein molecular weight marker (Bio-Rad).
Encapsulation of Hep-ATIII
To produce 10 ml sterically stabilized anti-HLA-DR unilamel-
lar immunoliposomes a two step protocol was used: The first step
included the derivatization of the anti-HLA-DR antibody: 0.6 ml
of 0.1 M of octyl glucoside (OG) was added to 6 ml of MES/NaCl
buffer. Then 3.30 mg of N-glutaryl-dioleoylphosphatidylethanola-
mine (NGPE) lipid (Sigma-Aldrich) was dissolved in 2 ml of
chloroform and added to a 50 ml round bottom flask. Chloroform
was evaporated in a rotary evaporator. OG in MES/NaCl buffer
was added to the dried film. Then 1.1 ml of 0.25 M 1-ethyl-3-(39-
(dimethylamino)propyl)carbodiimide (EDC) (Sigma-Aldrich) and
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and incubated at room temperature for 10 min, then adjusted to
pH 7.5. Anti-HLA-DR antibody (50 mg, clone 2.06, IgG1,
American Type Culture Collection (ATCC) dialyzed against
sodium borate buffer was added. This solution was incubated for
12 h at 4uC and afterwards dialyzed against PBS buffer. The
NGPE conjugated antibody was concentrated in a vacuum
concentrator.
The second step included the encapsulation of hep-ATIII and
binding of the antibody to the liposome: 40 mg of dioleoylpho-
sphatidic acid (DOPA) (Sigma-Aldrich) and 164 mg of dioleoyl-
phosphatidylethanolamine (DOPE) (Sigma-Aldrich) was dissolved
in 100 ml of chloroform in a round bottom flask connected to
a rotary evaporator. The chloroform was evaporated by vacuum
until a thin lipid film was formed. The NGPE conjugated antibody
and 1 ml hep-ATIII solution (20 mg/ml) was added to the dried
lipid film. This film was hydrated overnight at 4uC during which
liposomes formed. The liposomes were sized to 100 nm by 20
times extrusion through a 5-micron diameter pore polycarbonate
membrane filter using a Lipex extruder (Northern Lipids,
Burnaby, BC, Canada). The liposomes were dialyzed against
10 L of PBS buffer for 36 h. Efficiency of protein encapsulation
was determined by measurement of retained protein in the
supernatant after centrifugation of immunoliposomes by a bicinch-
oninic acid assay (BCA) (Pierce, Rockford, Ill). The phospholipids
concentration was measured using visible derivative spectroscopy.
The total amount of the lipids was 20 mg/ml. The total amount of
encapsulated protein was 0.05 mg/ml and the total amount of the
conjugated anti-HLA-DR antibody was 2.4610
4 mol/ml.
Conventional multilamellar liposomes were prepared as follows:
Phosphatidylcholine (PC) and cholesterol (both purchased from
Avanti Polar Lipids, Alabaster, AL) were dissolved in chloroform
(total concentration of lipids in chloroform was around 2 mg/ml)
and added to a 250 ml capacity round bottom flask. The
chloroform was evaporated from the flask using a rotary
evaporator for at least 4 h. A thin lipid film was formed on the
wall of the round bottom flask. Hep-ATIII protein was purged
with Argon gas for 10 min and added to the thin lipid film. The
lipid film was hydrated for 4 h at 4uC. The liposomes were formed
after the hydration. Liposomes were extruded 20 times through
a5mm polycarbonate membrane filter using a Lipex extruder.
The liposomes were centrifuged. The phospholipid concentration
was measured spectophotometrically using visible derivative
spectroscopy. The cholesterol was measured using the cholesterol
measuring kit from Sigma-Aldrich. The amount of the encapsu-
lated protein was measured by BCA as described above. The
concentration of PC was 20 mg/ml and that of cholesterol was
5 mg/ml. The liposomes were 1–2 mm in size and encapsulated
0.8 mg/ml hep-ATIII.
HIV-1 Env Pseudovirus Production and Titration
We used Env plasmids for HIV-1 pseudovirus production
representing the standard panel of clade B clones (PVO.4,
QH0692) and clade C clones (Du123.6, Du 151.2) from NIH
AIDS Research and Reference Reagent Program (ARRRP).
Stocks of single-round infectious HIV-1 Env pseudovirus were
produced by cotransfecting 293T/17 cells (1.7610
7 cells per T75
flask) with 2 mg of an HIV-1 rev/env expression plasmid and
12 mg of an env-deficient HIV-1 backbone plasmid (pSG3DEnv)
using Lipofectamine transfection reagent (Invitrogen, Grand
Island, NY). Pseudovirus-containing supernatant was harvested
24 h following transfection and clarified by centrifugation and
0.45-mm filtration. Single-use aliquots (1.0 ml) were stored at
280uC. The 50% tissue culture infectious dose (TCID50) for each
pseudovirus preparation was determined by infection of TZM.bl
cells as previously described [22]. A T-cell-line-adapted (TCLA)
strain of HIV-1 MN was obtained from the NIH ARRRP as
contributed by R. Gallo [23,24], and cell-free stocks were
generated using H9 cells as previously described [25].
HIV-1 Pseudovirus Inhibition Assay
Virus inhibition was measured using a luciferase-based assay in
TZM.bl cells as previously described [26]. This assay measures the
reduction in luciferase reporter gene expression in TZM.bl cells
following a single round of virus infection. Briefly, TZM.bl cells
were added (1610
4/well in a 100-ml volume) in 10% D-MEM
growth medium containing DEAE-dextran (Sigma-Aldrich) at
a final concentration of 11 mg/ml. Three-fold serial dilutions of
250 mg/ml non-activated ATIII, 50 mg/ml heparin, 15 mg/ml
hep-ATIII and 15 mg/ml 135 kDa ATIII complex stock solution
were performed in triplicate (96-well flat bottom plate) in 10% D-
MEM growth medium (100 ml/well) and added to the cells. An
amount of 200 TCID50 of virus was then immediately added to
each well in a volume of 50 ml, and the plates were incubated for
48 h at 37uC. Assay controls included replicate wells of TZM.bl
cells alone (cell control) and TZM.bl cells with virus (virus control).
Following incubation period, 150 ml of assay medium was
removed from each well and 100 ml of Bright-Glo luciferase
reagent (Promega, Madison, WI) was added. The cells were
allowed to lyse for 2 min, and then 150 ml of the cell lysate was
transferred to a 96-well black solid plate, and luminescence was
measured using a Victor 3 luminometer (Perkin Elmer, Hopkin-
ton, MA). The 50% inhibitory concentration (IC50) titer was
calculated as the serum dilution that caused a 50% reduction in
relative luminescence units (RLU) compared to the level in the
virus control wells after subtraction of cell control RLU.
In vitro Acute HIV Infection Assay Using Primary Isolates
For in vitro assays, human peripheral blood mononuclear cells
(hPBMC) from HIV-1-seronegative donors were obtained by
Ficoll-Hypaque gradient centrifugation of heparinized whole
blood. After 3 days of mitogen stimulation (6.25 mg/mL conca-
navalin A), hPBMC were re-suspended at a concentration of
1610
5 cells/ml in RPMI 1640 culture medium (Sigma-Aldrich)
supplemented with 10% fetal calf serum (Sigma-Aldrich), penicil-
lin (50 U/ml), streptomycin (50 mg/ml), L-glutamine (2 mM),
HEPES buffer (10 mM), and 50 U/ml interleukin-2 in 24-well
tissue culture plates (Becton Dickinson, San Jose, Ca). An HIV-1
inoculum of 1,000 50% tissue culture infective doses (TCID)/10
5
cells was added to the hPBMC for 2 h at 37uC and cells were
washed extensively. Hep-ATIII, conventional liposomes and
sterically-stabilized anti-HLA-DR immunoliposomes encapsulat-
ing hep-ATIII were added in serial dilutions at day 1 and day 4.
Fifty percent of medium was replaced at day 4. Each condition
was tested in triplicate. To determine viral inhibition, cell-free
culture supernatants were harvested and analyzed by an enzyme-
linked immunosorbent assay (ZeptoMetrix Corporation, Buffalo,
NY) for HIV-1 p24 antigen on day 7 of culture and compared
against a vehicle control. Different drug concentrations were used
in a virus-specific cell-based assay to measure inhibition. From
these data, the IC50, was calculated using the MacSynergy II
Software [27]. Controls for inhibition experiments included
vehicle buffer, bovine serum albumin (up to 30 mM) and a heparin
only control. Additionally, for the liposome inhibition assays,
empty liposomes were used as controls. Controls never reached
more than 25% inhibition compared to untreated controls. The
new integrase inhibitor 118-D-24, belonging to the azido-contain-
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drug with a known IC50 between 2 and 10 mM [28].
Treatment of Rhesus Macaques with Different Forms of
ATIII
For the non-human primate studies, Indian-origin rhesus
macaques were intravenously infected with a 50-fold 50%
monkey infectious dose (MID50) of SIVmac251, and followed for
more than 450 days after infection. Animals then received 0.8
mmol/kg, non-activated ATIII by the intravenous route daily for
4 days and then every 3 days for another 9 days. Hep-ATIII
was administered daily for the first 4 days at 0.6 mmol/kg.
Immunoliposome preparations were injected as 1.5 ml sub-
cutaneous administrations at day 1 and 2 with 0.3 nmol/kg
hep-ATIII.
Measurements of SIV Load
To measure SIV load, viral RNA was isolated from 200 mL
of plasma using the NucliSENS Isolation Kit (Biomerieux,
Lyon, France) according to the manufacturer’s protocol. RNA
was reverse transcribed in parallel with an SIV-gag RNA
standard using the gene-specific primer sGag-R 59CAC-
TAGGTGTCTCTGCACTATCTGTTTTG-39 with the follow-
ing conditions: the 50 mL reactions containing 16buffer
(250 mM Tris-HCL pH 8.3, 375 mM KCl, 15 mM MgCl2),
0.25 mM primer, 0.5 mM dNTPs (Roche), 5 mM dTT, 500 U
Superscript III RT (Invitrogen, Carlsbad, CA), 100 U RNase-
OUT (Invitrogen), and 10 mL of sample. RT conditions were
1 h at 50uC, 1 h at 55uC and 15 minutes at 70uC. Samples
were treated with RNase H (Stratagene, La Jolla, CA) for
20 min at 37uC. For the real-time PCR (RT-PCR) reactions the
EZ RT-PCR Core Reagents (Applied Biosystems, Foster City,
CA) were used according manufacturer’s protocol. Primer
sequences were used as described previously [29] with forward
primer s-Gag-F, 59-GTCTGCGTCATCTGGTGCATTC-39,
reverse primer s-Gag-R, 59-CACTAGGTGTCTCTGAC-
TATCTGTTTTG-39, and the probe s-Gag-P, 59-
CTTCCTCAGTGTGTTTCACTTTCTCTTCTGCG-39,
linked to Fam and BHQ (Invitrogen). All reactions will be
carried out on a 7300 ABI RT-PCR system (Applied
Biosystems) in triplicate according to the manufacturer’s
protocols.
Murine Model of HIV-1 Infection
Protection from HIV induced cytotoxicity in hPBMC was
measured in an acute HIV-1 infection model with 6 to 8-week
old female Nod/Scid/b2m
null mice from The Jackson Labora-
tory (Bar Harbor, ME). These mice were chosen because of their
lack of murine lymphoid cells in the spleen and superior
engraftment of hPBMC compared to other Nod/Scid mice [30].
This allows for the quantification of HIV-induced cytotoxicity in
engrafted hPBMC in mice as splenocytes are largely of human
origin. For Nod/Scid/b2m
null mice grafts, 10
7 freshly isolated
hPBMC were acutely infected in vitro with a multi-drug resistant
HIV-1 clone (GenBank no. AY351719, NIH no.7324-4) [31] at
1000 TCID50/ml and incubated at 37uC for 2 h. This primary
HIV-1 isolate showed 3.5-fold resistance to abacavir (ABC), 1.7-
fold resistance to didanosine (DDI), 3.6-fold resistance to
lamivudine (3TC), 2.3-fold resistance to stavudine (D4T), 5.2-
fold resistance to tenofovir (TDF), 1.4-fold resistance to
zalcitabine (DDC), and 464-fold resistance to zidovudine (AZT)
as determined by the Virologic PhenoSense
TM Assay [31]. Cells
were washed of excess virus and 3610
6 hPBMC were
administered by the intraperitoneal route into the Nod/Scid/
b2m
null mice. Twenty-five nmol/kg of hep-ATIII was adminis-
tered by intravenous route via the tail vein once daily. Mice
spleens were harvested after 14 days of hep-ATIII treatment,
splenocytes were isolated and red blood cells were lysed with BD
Pharm Lyse
TM lysing solution (BD Bioscience, Bedford, MA).
Splenocytes were counted under a light microscope after Trypan
Blue exclusion staining.
Measurement of in vitro Cytotoxicity
To test for cytotoxicity in the in vitro inhibition assays, un-
infected drug-treated cytotoxicity controls were maintained at the
highest concentration of drug tested, and assessed by Trypan Blue
dye exclusion and Neutral Red staining. Additionally, viability of
cells was tested at day 5 after drug addition with the Guava
Technologies EasyCyte Plus Flow Cytometer system (Guava
Technologies, Hayword, CA). The Guava ViaCountH Assay was
used to test for apoptotic cells.
Measurement of in vivo Cytotoxicity
Mice (C57BL/6, 5 per group) were injected with different
amounts of hep-ATIII loaded immunoliposomes. Weight, CBC
and blood chemistries were measured.
Affymetrix GeneChipH Rhesus Macaque Genome Array,
Gene-expression and Network Analysis
To measure the effect of hep-ATIII on gene expression,
rhesus macaque PBMC were purified from the blood of hep-
ATIII treated monkeys and vehicle treated controls. Total RNA
from cells was purified after shredding cells using the
QIAshredder homogenizer (Qiagen, Valencia, CA) with
RNAeasy spin-columns (Qiagen) according to manufacturer
protocol. Integrity and concentration of RNA samples was
tested using an Agilent BioAnalyser and applied to an
Affymetrix system setup consisting of target preparation, target
hybridization, probe array washing, staining and probe array
scan. The Affymetrix GeneChipH Rhesus Macaque Genome
Array was used to analyze gene-expression patterns activated by
hep-ATIII treatment. This array enables whole genome gene-
expression measurement of 47,000 rhesus macaque transcripts.
Gene expression and protein network analysis was performed
using the Ingenuity 8.0 software (Ingenuity Systems, Redwood
City, CA).
Complete Blood Count and Peripheral Blood CD4+ T
Lymphocyte Count for Rhesus Macaques and C57BL/6
Mice
Complete Blood Count (CBC) testing white blood cell count
(WBC), red blood cells (RBC), hemoglobolin (HGB), hematocrit
(HCT), mean red cell volume (MCV), mean cell hemoglobin
(MCH), platelet count (PLT) and mean platelet volume (MPV) was
performed using the ADVIA Hematology System (Bayer,
Leverkusen, Germany) according manufacturers protocol. Periph-
eral blood CD4
+ T lymphocyte counts were calculated by
multiplying the total lymphocyte count by the percentage of
CD3
+CD4
+ T cells determined by mAb staining and flow
cytometric analysis [32].
Data Analysis
The statistical significance of differences between groups was
determined using the program GraphPad Prism 4.0 (GraphPad
Software, La Jolla, CA). A P value of ,0.05 was considered
statistically significant. Statistical analysis was performed by use of
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Error bars represent standard error of the mean (S. E.).
Results
Anti-viral Activation of ATIII
Anti-viral capacity of ATIII was activated by overnight
incubation with heparin at 37uC. This resulted in a mixture
containing three compounds, which we subsequently separated by
Sephacyl S100 FPLC. We found 1–3% w/w of a 135 kDa ATIII
polymer with a retention volume of 7–8 ml. Ninety-five to ninety-
nine % (w/w) of the mixture was 66–68 kDa hep-ATIII, in which
heparin was bound to ATIII, at a retention volume of 10–14 ml.
At approximately 35 kDa a protein-free fraction comprised of
unbound heparin polymer was contained (15–19 ml retention
volume) (Fig. 1A). The amount of this free heparin was calculated
to be routinely below 5% (w/w) of the total mixture. We used
fractionated hep-ATIII for our experiments.
We confirmed the purity of our fractionated hep-ATIII (66–
68 kDa) preparations by SDS-PAGE and silver staining. We found
that these hep-ATIII fractions were routinely more than 99% pure
(Fig. 1B).
Anti-viral Activity of Activated and Non-activated ATIII in
a Single-round HIV Pseudovirus Inhibition Assay
We used the single-round HIV inhibition assay to measure the
anti-viral activity of activated ATIII, hep-ATIII, and compared
that with unmodified ATIII, the 135 kDa ATIII complex and
a heparin control. This system allowed the measurement of
inhibition effects on all phases in a virus’ life-cycle during one
round of replication. To investigate the susceptibility of different
HIV-1 envelopes to hep-ATIII inhibition we used pseudoviruses
with clade B (PVO.4, QH0692.42) and clade C (Du123.6,
Du151.2) envelopes. We found that the 66–68 kDa fraction,
containing heparin-activated ATIII, exhibited anti-viral activity.
The IC50 of hep-ATIII was between 20–100 nM, and in-
dependent of envelope usage (Fig. 2). Unmodified ATIII had
no inhibitory activity (Fig. 2) as well as the 135 kDa ATIII
polymer (data not shown). Both demonstrated no inhibition as
defined as inhibition below 25% in the pseudovirus inhibition
assay. We also observed that heparin had an IC50 of 8 mM
(Fig. 2), comparable to what has been previously reported.
Anti-viral Activity of Activated and Non-activated ATIII in
PBMC Acutely Infected with Drug-resistant HIV-1
Anti-HIV-1 therapy that targets viral proteins must contend
with the virus’ ability to rapidly evolve leading to the emergence of
Figure 1. Characterization of heparin-activated ATIII. (A) Sepharcyl S100 A ¨KTA FPLC of purified hep-ATIII. A 9–14 ml fraction was separated,
termed as hep-ATIII and used for our experiments. Detection at 260 nm for protein detection and 280 nm for heparin detection is shown. (B) Hep-
ATIII purity and molecular weight were also determined by SDS-PAGE and silver staining (Bio-Rad kit) of a 15% slab gel. For molecular weight
determination a low-range protein molecular weight marker (Bio-Rad) was used. Lane 1:2 mg hep-ATIII; lane 2: phosphorylase B (97 kDa), serum
albumin (69 kDa), carbonic anhydrase (31 kDa), trypsin inhibitor (21.5 kDa), aprotinin (6.5 kDa).
doi:10.1371/journal.pone.0048234.g001
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while stimulating host innate immunity may be able to circumvent
antiviral resistance. We have previously shown that non-activated
ATIII exerts limited anti-HIV-1 activity and has only limited
effects on host cell gene expression. The anti-HIV-1 activity of
ATIII can be augmented through overnight incubation with
heparin [16], which results in non-covalent attachment of heparin
to ATIII, creating activated hep-ATIII. We sought to determine if
hep-ATIII could overcome current limitations in drug treatment
options for multidrug resistant HIV.
We tested the anti-HIV activity of hep-ATIII against an array of
primary isolates from different clades, with T-cell tropism (X4),
macrophage tropism (R5) or dual-tropism (X4R5), and differing in
drug resistance profiles. After infection of hPBMC with the various
HIV isolates, we then added hep-ATIII at the indicated
concentrations (at day 1 and 4 of infection), and followed the
infection by p24-antigen ELISA for 7 days. We then used the
resulting dose-response curves for day 7 to calculate IC50 values.
Our experiments demonstrated that hep-ATIII exhibited potent
anti-HIV activity that was independent of prior drug exposure,
clade or co-receptor usage (Table 1). Importantly, we found that
the anti-viral activity of hep-ATIII was observed at therapeutically
favorable levels with IC50 values ranging from 16–240 nM
(Table 1), which was similar to those observed in the pseudovirus
inhibition assays (Fig. 2).
Effect of Hep-ATIII on HIV-induced Cytotoxicity in
Engrafted hPBMC in Nod/Scid/b2m
null Mice
We hypothesized that the immunomodulatory effects of hep-
ATIII might not only inhibit HIV replication in target cells, but
may also protect infected cells and uninfected bystander cells from
HIV-related cytotoxic effects. We utilized the hPBMC engrafted,
HIV-infected Nod/Scid/b2m
null mice to test this hypothesis.
These mice lack murine lymphoid tissue and NK cell function,
enabling superior engraftment of hPBMC compared to other
Nod/Scid mice [30]. To simulate therapy of the challenging
multidrug resistant HIV patient, we engrafted mice with hPBMC
that were infected in vitro with a highly resistant HIV-1 isolate. We
assessed whether daily treatment with low doses of hep-ATIII
(25 nmol/kg) might reduce virus-induced hPBMC cytotoxicity.
We used 5 Nod/Scid/b2m
null mice per non-engrafted group, non-
Figure 2. Effect of heparin-activated ATIII in pseudovirus inhibition assay. Pseudoviruses with clade B envelopes (in A and C) and clade C
envelopes (in B and D) were treated with three fold dilutions of heparin-activated ATIII (hep-ATIII), unmodified ATIII and heparin. Percentage of
inhibition was calculated by comparing of residual luciferase activity and untreated control. Experiments were done in triplicates. Data are shown as
mean 6 S.E.
doi:10.1371/journal.pone.0048234.g002
Table 1. IC50 of hep-ATIII for drug resistant HIV-1
HIV-1 isolate Co-receptor IC50 (nM)
92/TH/006 R5 16
M46I/L63P/V82T/I84V
a R5X4 45
G762-3
b R5X4 53
RF R5X4 74
RF/V82F/I84V
c R5X4 107
G691-6
d R5X4 205
N119 X4 213
10076-4
f R5X4 238
aresistant to the structurally diverse protease inhibitors: MK-639, XM323, A-
80987, Ro 31-8959, VX-478, SC-52151 [70].
bAZT resistant, pre-drug [71].
cprotease resistant derived from HIV-1 RF [72].
dAZT resistant, post-drug [71].
eNevirapine resistant [73].
fmulti-drug resistant HIV-1, fold resistance as determined by the ViroLogic
PhenoSense
TM Assay [15,31]: ABC: 3.8; DDI: 1.6; 3TC: greater than upper limit of
assay detection; D4T:1.9; TDF:1.3; DDC:1.8, AZT:6.3.
doi:10.1371/journal.pone.0048234.t001
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ATIII treated uninfected group, vehicle treated infected group and
hep-ATIII treated infected group (Fig. 3). We utilized a strain of
HIV-1 that produced more than 90% virus-associated cell death of
infected hPBMC in mice. We found that there was a 100%
increase in splenocyte number after 14 days of treatment with hep-
ATIII (P=0.008, Mann-Whitney test) (Fig. 3) compared to
untreated HIV-infected hPBMC engrafted control mice, suggest-
ing protection of hPBMC from HIV cytotoxicity.
This demonstration of in vivo efficacy of hep-ATIII against HIV
in the humanized mouse model prompted us to further test hep-
ATIII in a more sophisticated non-human primate model of
chronic lentiviral infection.
Activity of Heparin-activated and Non-activated ATIII in
Rhesus Macaques
Although there are numerous reports describing the in vitro anti-
viral activity of the serpins a1-anti-trypsin [12,33] and SLPI
[11,17,18], there are no reports demonstrating their in vivo anti-
viral efficacy. One obstacle to the in vivo assessment of the
therapeutic potential of serpins may be that of generating and
delivering an optimally activated form of the protease inhibitors.
We utilized the rhesus macaque model of simian immunodefi-
ciency virus (SIV) infection to assess whether variably activated
forms of the serpin ATIII could inhibit viral replication. We have
previously demonstrated that SIV strains are inhibited to a similar
degree by ATIII as HIV-1 isolates [14].
Indian-origin rhesus macaques (Macaca mulatta) were infected by
the intravenous (i. v.) route with 50-fold MID50 of SIVmac251 and
were followed clinically for more than 450 days post infection.
Viral loads of animals at the time of drug administration were
stable with not more than 0.25 log10 variation between measure-
ments in any given animal, and with viral loads routinely between
10
4–10
6 copies per ml for each of the different animals. Peripheral
blood CD4
+ T lymphocyte counts were between 10
4 and 10
5 cells
per ml.
We first tested non-activated ATIII in 3 rhesus macaques. We
based our dosing regimen for non-activated ATIII on a baboon
model of sepsis, in which ATIII administration between 10 to 20-
fold the physiological level (2.4 mM) was required to initiate an
anti-inflammatory response to prevent disseminated intravascular
coagulation [34]. A comparable dose had also been shown to be
non-cytotoxic in primates [35]. Based on this, 0.8 mmol/kg ATIII
was injected daily for 4 days during a loading phase and then
applied every 3
rd day for a 14-day period. This administration
schedule was chosen to prevent a significant decline in effective
plasma drug concentration during the treatment period based on
the 2.5–4.8 day half-life of ATIII measured by biologic and
immunologic assays [36,37,38]. We confirmed lack of toxicity by
both CBC and blood chemistries (data not shown). Although
ATIII was administered at supra-physiologic doses we could not
detect anti-viral activity as measured by changes in plasma viral
RNA levels (Fig. 4A/B).
Hep-ATIII anti-viral activity is up to more than 10-fold more
potent than that of ATIII [16]. As our animals appeared to
tolerate the dose of non-activated ATIII without side effects, we
administered a comparable dose of hep-ATIII for four days. Hep-
ATIII exhibits a reduced half-life of 2 days [36,37,39]. From these
data we estimated that daily dosing for 4 days with 0.6 mmol/kg
will produce serum concentrations above 10 mM, more than 4-fold
the physiologic concentration of ATIII. Using 3 rhesus macaques,
we observed a 0.9 log10 reduction in plasma viral load seven days
after the first administration (day 7) of hep-ATIII, amounting to an
80% reduction in circulating virus (P=0.004, paired T-test). The
viral RNA reduction persisted for 11 days after the discontinuation
of the hep-ATIII treatment (Fig. 4C/D). Thus, we demonstrate
an in vivo therapeutic effect, and that this serpin activity is
dependent on proper biochemical activation.
In vitro Anti-viral Activity of Hep-ATIII after Encapsulation
into Sterically Stabilized Anti-HLA-DR Immunoliposomes
In addition to proper biochemical activation, another obstacle
to the successful therapeutic use of serpins may be in their
pleiotropic activity, and potential for negative off-target side
effects. We hypothesized that by targeting hep-ATIII specifically
to tissues in which HIV replication is most robust, we could
simultaneously increase therapeutic efficacy and reduce off-target
drug exposure. We thus sought to determine if the therapeutic
Figure 3. Effect of heparin-activated ATIII on HIV-induced cytotoxicity in NOD/Scid/b2m
null mice. (A) To measure HIV-induced
cytotoxicity, splenocytes from NOD/Scid/b2m
null mice engrafted with HIV-infected hPBMC were quantified after 14-day incubation. hPBMC were
purified by Ficoll-Hypaque gradient centrifugation, acutely infected at an MOI of 0.001 with a multidrug resistant HIV clone (GenBank no. AY351719,
NIH no.7324-4) and incubated in vitro at 37uC for 1 hour. 3.5610
6 acutely infected hPBMC were administered via the peritoneal route into NOD/Scid/
b2m
null mice (n=5). These mice were then treated with a daily intravenous dose of 25 nmol/kg hep-ATIII. Splenocytes were counted under a light
microscope after Pharma Lyse
TM treatment and Trypan Blue exclusion staining. Controls included non-engrafted animals (with or without vehicle
buffer treatment), uninfected animals not treated with hep-ATIII (vehicle uninfected control) and animals treated with hep-ATIII (hep-ATIII uninfected
control). , P,0.01, Mann-Whitney test. Data are shown as mean 6 S.E.
doi:10.1371/journal.pone.0048234.g003
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ATIII into immunoliposomes. As serpins lack the ability to
specifically traffic to the lymph nodes, the primary tissue of viral
replication, we sought to facillitate delivery of hep-ATIII to the
lymph nodes by encapsulation into sterically stabilized anti-HLA-
DR immunoliposomes (termed ET-ATIII) [40]. These liposomes
enable dissemination of drugs directly to the lymphatic system,
and also primarily home in on HIV-1 infected cells expressing the
HLA-DR receptor [40].
We assessed the viral inhibitory activity of unencapsulated hep-
ATIII, hep-ATIII encapsulated into conventional liposomes
lacking anti-HLA-DR, and ET-ATIII against the dual-tropic
(X4R5) HIV 89.6, and the macrophage-tropic (R5) SF162 in cell
culture. These two HIV-1 isolates are derived from two different
viral reservoirs: 89.6 was isolated from PBMC, and SF162 from
the cerebrospinal fluid. 89.6 is a prototype for syncytium-forming,
highly cytopathic HIV-1 viruses that replicate to high titers in cells
bearing either CXCR4 or CCR5 receptors, reflective of isolates
that may be found in individuals with AIDS [41]. In contrast,
SF162 has more restricted co-receptor usage, is less cytopathic and
more typical of primary, transmitted HIV isolates [42].
We infected hPBMC with SF162 and 89.6, and treated cells
with hep-ATIII either unencapsulated or encapsulated into either
conventional liposomes or sterically-stabilized anti-HLA-DR
immunoliposomes (ET-ATIII) (Table 2). We found that encap-
sulation into immunoliposomes increased the anti-viral potency of
hep-ATIII 107–150–fold, resulting in sub-nanomolar IC50 values
of 0.4–0.7 nM. In contrast the use of conventional liposomes had
only a limited effect on hep-ATIII potency. The IC90 for
immunoliposomes was 3.7 nM for the 89.6 strain and 4.1 nM for
the SF162 strain. We also compared the anti-HIV activity of ET-
ATIII to that of the integrase inhibitor, 118-D-24. We observed an
IC50 for 118-D-24 of 1750 nM, similar to what has been
previously reported [28], suggesting a 1000-fold greater activity
for ET-ATIII on a molar basis (Table 2). A vehicle liposome
control was used for both liposome constructs to confirm that the
liposomal vehicle did not have antiviral properties itself, consistent
with prior studies [43].
Conventional liposomes and sterically-stabilized immunolipo-
somes have been used to encapsulate imaging reagents, small
molecule drugs and proteins in both pre-clinical experiments and
clinical settings, including in HIV patients, to minimize drug side-
effects by increasing target tissue specificity
[19,40,43,44,45,46,47]. There has been no cell toxicity reported
after administration of proteins encapsulated in conventional or
sterically stabilized liposomes [43,48,49]. To assess the therapeutic
Figure 4. In vivo anti-viral activity of non-activated and heparin-activated ATIII in rhesus macaques. (A) Viral loads as RNA copies/ml of
chronically SIVmac239 infected rhesus macaques treated with 0.8 mmol/kg non-activated ATIII (n=3) and (B) corresponding log10 reduction of viral
load of same treatment group. (C) Viral loads as RNA copies/ml of chronically SIVmac239 infected rhesus macaques treated with 0.6 mmol/kg heparin-
activated ATIII (n=3) and (D) corresponding log10 reduction of viral load of same treatment group. Administration via i. v. inoculation is shown at
indicated time points depicted by arrows. Viral load was measured and compared to animals before treatment (day 0). *, P,0.05, paired T-test,
compared to pre-treatment (day 0). Data are shown as mean 6 S.E.
doi:10.1371/journal.pone.0048234.g004
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dose range. We calculated TI as the ratio of the 50% cytotoxic
dose (CD50) to the IC50. To measure the CD50 we tested the
effect of ET-ATIII on cell viability using the Guava ViaCountH
Assay. For these assays we used hPBMC from an HIV-1 infected
patient as the indicator of cytotoxicity, as these best reflect cell
populations that would be targeted by the liposome treatment
in vivo. Additionally, we also assessed the toxicity of the liposomes
against endothelial cells as ATIII is known to affect this cell type,
inducing the release of anti-inflammatory prostacyclin and
prostaglandins [7,8]. We found no significant decrease in viability
of either cell population in response to an escalating dose of
encapsulated hep-ATIII (3–30 nM). We found that encapsulated
hep-ATIII had a very favorable TI of .100. A TI of .10 is
considered feasible for an antiviral drug.
In vivo Anti-viral Activity of hep-ATIII after Encapsulation
into Sterically Stabilized Anti-HLA-DR Immunoliposomes
Under normal physiologic conditions, ATIII is not detectable
in the lymphatic system [50]. As the lymph nodes are a major
compartment for HIV-1 replication, we hypothesized that
targeting hep-ATIII directly to the lymphatic system may
increase the in vivo activity of hep-ATIII in our chronically SIV-
infected macaque model. It has been previously shown that
sterically stabilized anti-HLA-DR immunoliposomes accumulate
in cervical and brachial lymph nodes, suggesting that they may
effectively target HLA-DR positive cells, i.e. monocytes/macro-
phages and activated CD4
+ T lymphocytes that are the primary
cellular targets of HIV-1 [19]. Hep-ATIII was encapsulated in
immunoliposomes (0.05 mg/mL) of 100 nm diameter with
4610
4 mol/ml anti-HLA-DR antibody incorporated. We sub-
cutaneously injected chronically two SIV-infected animals with
0.3 nmol/kg of ET-ATIII. The overall quantity of hep-ATIII
inoculated was 2000-fold less than the dose of unencapsulated
hep-ATIII used in our previous in vivo experiments. We
determined this dose based on two prior findings: firstly, our
in vitro inhibition data suggested that ET-ATIII was at least 23-
fold more effective than hep-ATIII compared to the lowest
IC50 found for the resistant strains (Table 1); secondly, prior
reports have suggested a 100-fold increase of efficacy in anti-
HIV-1 drugs activity when these are delivered directly to lymph
tissue [40]. We observed that ET-ATIII decreased plasma SIV
viral RNA by an average of 2 log10 (range 0.97–2.5 log10)a t
day 7 (Fig. 5A/B) - 5 days after the 2
nd treatment,
demonstrating the potent anti-viral activity of ET-ATIII.
Control immunoliposomes did not alter viral load (Fig. 5B).
To further investigate the limits of safe dosing of ET-ATIII, we
used 5 wild type C57BL/6 mice per group to assess for systemic
toxicity of high doses of ET-ATIII. We tested concentrations of
ET-ATIII up to 30 nmol/kg, 100-fold the effective dose for in vivo
SIV inhibition. We measured the complete blood count (CBC) to
assess for the hematologic effects of the ET-ATIII formulation. In
particular, the hematocrit (HCT) was used as a surrogate marker
for internal bleeding, a potential side effect of the use of hep-
ATIII. We found no significant change in animal weight, white
blood cell count or HCT. All other blood parameters as well as
liver function tests were within the expected normal range (data
not shown). Thus, no in vivo cytotoxicity could be detected in mice
at concentrations significantly in excess of the therapeutically
effective anti-viral dose.
Gene Expression in PBMC from Hep-ATIII Treated Rhesus
Macaques
The exact molecular mechanisms by which hep-ATIII exerts its
anti-HIV effect in vivo is unknown. We used transcriptional
profiling of PBMC taken from SIV-infected, hep-ATIII-treated
rhesus macaques to identify host molecular pathways that might
contribute to viral suppression in an extension of our prior in vitro
investigations [9]. We compared the transcriptional profiles of
47,000 mRNAs at day 7 post-hep-ATIII therapy to the pre-
treatment controls, when SIV inhibition was maximal. We also
compared transcriptional profiles from day 15 post-therapy, when
SIV inhibition had dissipated, to pre-treatment controls. We found
that the expression of only a limited number of genes were
significantly affected (P,0.01, DDCt method) by hep-ATIII
therapy when compared to pretreatment (Fig. 6). We grouped
genes into three groups dependent on the gene-expression pattern
at the treatment time point compared to pre-treatment (Fig. 6A/
B/C; abbreviations of gene names are specified in Table S1). (1)
We identified 18 genes and 15 gene loci that were over-expressed
at both day 7 and day 15 in relation to pretreatment (Fig. 6A). (2)
We found 20 genes and 12 loci that were significantly down-
regulated at the time of maximal inhibition (day 7) compared to
pre-treatment controls, but were up-regulated by day 15
compared to pre-treatment controls, when inhibition had di-
minished (Fig. 6B). (3) One gene and 2 loci were up-regulated
after 7 days but down-regulated at day 15 (Fig. 6C). We also
found that six genes and 7 loci were down regulated at both time
points after therapy (Fig. 6C).
Network Analysis of Hep-ATIII-induced Interactomes
during Lentiviral Replication in vivo
Interactomes describe relationships between genes that may be
functionally linked. Certain genes may be central to the
interactome, and modulation of these key genes may exert
disproportionate effects on the other genes in the interactome.
In order to identify genes that were central to the activity of hep-
ATIII, we have previously analyzed the expression of 84 key genes
of certain pathways in hep-ATIII treated, HIV-infected hPBMC
in vitro, and found NFkB and prostaglandin synthetase-2 (PTGS2)
to be highly regulated by hep-ATIII [9]. In the present study, we
extended our analysis to a whole genome expression profile of
PBMC from hep-ATIII-treated, SIV-infected rhesus macaques,
evaluating 47,000 transcripts in all.
Applying Ingenuity-based network analysis to these gene
expression profiles we once again identified NFkB in one network
and ERK1/2 and PTGS2 in another network central to the two
highest scoring regulatory networks modulated by hep-ATIII
treatment (Fig. 7, Fig. 8, Fig. S1 contains explanation of
network symbols). Thus, in this comprehensive analysis of
transcriptional activation by hep-ATIII, we have confirmed that
NFkB and ERK1/2-PTGS2 are the likely major effectors of hep-
Table 2. IC50 of hep-ATIII in different liposome formulations.
Formulation HIV-1 isolate IC50 (nM)
Free hep-ATIII control 89.6 60
SF162 75
Conventional Liposomes 89.6 24
SF162 22
ET-ATIII 89.6 0.4
SF162 0.7
doi:10.1371/journal.pone.0048234.t002
In vivo Inhibition of ATIII
PLOS ONE | www.plosone.org 9 November 2012 | Volume 7 | Issue 11 | e48234Figure 5. In vivo anti-viral activity of ET-ATIII in rhesus macaques. Chronically SIVmac239 infected rhesus macaques (n=2) were treated with
1.5 ml ET-ATIII (0.3 nmol/kg encapsulated hep-ATIII) at indicated time points depicted by arrows. (A) Viral load of ET-ATIII treated animals as RNA
copies/ml. (B) Log10 reduction of viral load. Vehicle liposomes were used as a control. Viral load was measured and compared to animals before
treatment (day 0). Data are shown as mean 6 S.E.
doi:10.1371/journal.pone.0048234.g005
Figure 6. Changes in gene expression in PBMC induced by hep-ATIII treatment of chronically SIV-infected rhesus macaques. The
GeneChipH Rhesus Macaque Genome Array was used to assay genome-wide RNA expression (47,000 transcripts) in rhesus macaque PBMC before and
after hep-ATIII treatment (n=3). Differential gene expression comparison of time points when lentiviral replication was observed (day 7) and after
viral replication returned to baseline (day 15) for the three monkeys are shown. Only loci or genes that were significantly (P,0.01, DDCt method) up-
regulated (red) and down-regulated (green) in comparison to pre-treatment controls are shown. A 3-step color contrast for low, medium and high
gene expression change was used. (A) Group of genes significantly up-regulated at the day 7 and 15 day time points compared to pre-treatment
controls. (B) Genes significantly down-regulated at day 7 time point but significantly up-regulated at the day 15 time point compared to pre-
treatment controls. (C) Genes either significantly up-regulated at the 7 day time point and down-regulated at the 15 day time point, or else
significantly down-regulated at both time points compared to pretreatment controls. Full names of genes are given in Table S1.
doi:10.1371/journal.pone.0048234.g006
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before [9].
Discussion
Serpins are induced rapidly following virus infection as part of
a complex host innate immune response [7]. Mounting clinical
evidence demonstrates an association between increased levels of
serpin expression and either reduced HIV acquisition in
uninfected individuals or delayed disease progression in chron-
ically infected individuals [12,13,14,51,52,53,54,55]. For exam-
ple, serpins have been found to be present at high levels in the
cervical fluids of uninfected but repeatedly HIV-1 exposed sex
workers [56]. ATIII, a serpin with functions in the coagulation
cascade, was shown to have antiviral activity in vitro against not
only HIV but HCV and HSV as well [9,14,15,16,57]. We are
beginning to recognize that the serpins may have broad roles in
the innate immune response, which in the case of ATIII includes
an anti-inflammatory function in sepsis [58], anti-angiogenesis in
tumor growth [59], and chemotaxis for neutrophils, human
peripheral blood lymphocytes and monocytes [60,61,62]. The
role of serpins as adjuvants of the innate immune system may
suggest a potentially novel application for serpins in antiviral
therapy.
Although the arsenal of small molecule HIV inhibitors
continues to grow, drug resistance remains an important obstacle
to long-term HIV therapy. Modulators of the innate immune
system are attractive therapeutics because they act indirectly on
the virus through multiple host pathways, and so are not as
vulnerable to the evolution of viral resistance mutations. Indeed,
our results suggest that ATIII may be an effective part of a salvage
regimen for patients with highly drug resistant HIV strains. We
also found that when appropriately modified and targeted through
Figure 7. Highest scoring network after interactive network analysis of gene expression changes induced after hep-ATIII treatment
of SIV-infected rhesus macaques. The highest scoring primary transcriptional network activated by hep-ATIII treatment of chronically infected
rhesus macaques, at a time point when viral replication is inhibited by hep-ATIII (day 7), is shown. Rx (orange): potential medication treatment
options, BM (green): possible biomarkers. Network analysis was performed using Ingenuity 8.0 software. Explanation for symbols is given in Figure
S2.
doi:10.1371/journal.pone.0048234.g007
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a favorable TI .100 and no obvious negative effects in murine
and nonhuman primate models.
Our experiments suggest that the precise biochemical modifi-
cation and packaging of ATIII is critical to its therapeutic utility. It
is well described that the various biological functions of ATIII are
dependent on its tertiary structure [59,63]. This structure-de-
Figure 8. Second-highest scoring network after interactive network analysis of gene expression changes induced after hep-ATIII
treatment of SIV-infected rhesus macaques. The second-highest scored network activated by hep-ATIII treatment of chronically SIV-infected
rhesus macaques, at a time point when viral replication is inhibited by hep-ATIII (day 7), is shown. Network analysis was performed using Ingenuity
8.0 software. Explanation for symbols is given in Figure S2.
doi:10.1371/journal.pone.0048234.g008
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HIV as well. Interestingly, in vitro, heparin-activated ATIII and the
thrombin-ATIII complex showed the highest level of HIV-1
inhibition, followed by pre-latent ATIII [15,16]. A relaxed form of
ATIII has a 50% reduced inhibitory activity, whereas HIV
inhibition in vitro is negligible for the L-isoforms of ATIII [14]. In
vivo as well, ATIII antiviral activity appears to be dependent on
biochemical modification: CD8
+ T cells of HIV long-term non-
progressors (LTNP) exhibit enhanced ability to activate ATIII that
may be partially responsible for the reported non-cytolytic
inhibition of HIV-1 in this cohort [64].
ATIII is predominately in its S-configuration in blood at
a physiological concentration of about 2.4 mM. To determine
whether modification of ATIII has an effect on in vivo therapeutic
HIV activity, we assessed three forms of the protein: non-activated
ATIII, heparin-activated ATIII - both given intravenously - and
liposomally encapsulated ATIII given subcutaneously. Non-
activated ATIII, at a concentration sufficient to reduce in-
flammation in a baboon model of sepsis [34], and at 10–20-fold
normal physiologic concentrations, did not impede viral replica-
tion. In vitro experiments had demonstrated that the anti-HIV
activity of ATIII could be enhanced through heparin activation
[16], and in concordance with this we found that intravenous
administration of hep-ATIII resulted in a modest inhibition of
viral replication in vivo, confirming the importance of ATIII
activation.
However, we observed the most potent inhibition of plasma
virus when ATIII was packaged in immunoliposomes and
delivered subcutaneously. There are several possible explanations
for this observation: (1) It is likely that unencapsulated hep-ATIII
is not specifically transported to lymph nodes, a tissue that harbors
viral replication [65], while in contrast, anti-HLA-DR immuno-
liposomes likely transport ET-ATIII to this location [19]. (2)
Follicular dendritic cells (FDC) may stimulate viral replication in
lymphocytes, and it has been demonstrated that serpins may
interfere with this process [66]. (3) HIV disease progression is
associated with ATIII deficiency in blood [51,52,67]. Nevertheless,
there is likely considerable circulating anti-HIV serpin activity in
plasma, such that the serpin anti-HIV activity in plasma may be
saturated, and intravenous inoculation of hep-ATIII into the
plasma has limited additive effect. In contrast subcutaneous
administration of ET-ATIII targeting lymphoid organs maybe
more effective because baseline serpin activity in lymphoid organs
is minimal.
We probed the underlying mechanism of hep-ATIII anti-HIV
activity using software-supported interactome analysis, which
allowed us to identify key host cell factors that are immediately
downstream of drug treatment, and which in turn modulate the
expression of overarching gene networks. We previously found
that hep-ATIII activated two interactomes in HIV-1 infected
PBMC: one interactome dependent on the NFkB transcription
factor and a second interactome anchored by ERK1/2. These
host factors are known to significantly impact HIV-1 replication.
We now have expanded our analysis of transcriptional changes
downstream of treatment with hep-ATIII, and studied these
changes in the significantly more complex in vivo environment.
Once again we found networks regulated by NFkB (Fig. 7) and
ERK1/2-PTGS2 (Fig. 8) associated with hep-ATIII treatment
confirming earlier in vitro results from PBMC acutely infected with
HIV-1 [9]. There is a great need to counter HIV-induced
inflammation and its consequences on the central nervous system
(CNS) including HIV dementia. In the current studies we found
that hep-ATIII treatment down-regulated NFkB after 7 days. This
is important since the NFkB dimer consisting of p50 and RelA is
considered to be the largest contributor to activation of HIV
transcription and inflammation [68].
Our second network was centered around ERK1/2 and seems
to be dependent on PTGS2, an HIV inhibitory host cell factor
described earlier [9]. Thus, another possible mechanism by which
hep-ATIII might prevent HIV-induced dementia is through its
anti-inflammatory effect since prostaglandins were found to block
inflammation through inhibition of HIV-1 Tat-mediated ERK1/2
activation [69].
There are several limitations to these studies. (1) In our
investigation of virus-induced cytotoxicity in the spleens of
humanized mice, we have not characterized the specific cellular
populations that are preserved in contrast to those that are lost,
nor have we determined the mechanism by which hep-ATIII may
prevent cytotoxicity. (2) We have not provided a mechanism for
viral rebound after treatment with ET-ATIII. Our gene expression
analyses suggest that the mechanism of ET-ATIII is through
recruitment of innate antiviral mechanisms. Although it is unclear
whether HIV can rapidly evolve resistance to host innate factors in
such a rapid timeframe, we suspect that the rebound is most likely
due to the clearance of ET-ATIII from the host, and hence loss of
its suppressive activity. (3) Our non-human primate pilot studies
are limited by the number of animals available, but we believe
provide justification for a larger scale trial. Clearly testing a more
prolonged administration regimen is needed to more fully evaluate
the safety and efficacy of ET-ATIII as an anti-HIV therapeutic.
In conclusion, our data suggest that activated ATIII targeted to
lymph nodes may have substantial in vivo activity against HIV-1.
Further understanding of the mechanisms by which hep-ATIII
interferes with HIV replication in lymphoid tissues might have
important implications for the design of therapeutic strategies that
harness the innate immune system for both its direct antiretroviral
potential and its ability to modulate the adaptive immune
response.
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